{"description":"Same event may appear as both SAE and non-SAE but are distinct events. An event may be categorized as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. Safety analysis set evaluated. All-Cause Mortality: the total number of deaths during study, from first dose and up to the end of the study are reported for all treated participants and includes deaths which occurred after 90 days post last dose of study intervention.","eventGroups":[{"deathsNumAffected":2,"deathsNumAtRisk":4,"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"EG000","otherNumAffected":4,"otherNumAtRisk":4,"seriousNumAffected":3,"seriousNumAtRisk":4,"title":"Elranatamab"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Anaemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Leukopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Lymphopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":4}],"term":"Neutropenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Vertigo"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Diarrhoea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Injection site reaction"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Pyrexia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":4}],"term":"Cytokine release syndrome"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Hypogammaglobulinaemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Bronchitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Conjunctivitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Cytomegalovirus infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Cytomegalovirus infection reactivation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Nasopharyngitis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Oral candidiasis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Otitis media"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Fall"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Skin abrasion"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Hypoalbuminaemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Hypokalaemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Hypophosphataemia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Dysgeusia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Headache"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Neuropathy peripheral"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Oropharyngeal pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Rash"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Insomnia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":4}],"term":"Pneumonia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Tooth loss"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Weight decreased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Wound"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Arthralgia"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Death"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Malaise"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4}],"term":"Pneumonia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4}],"term":"Sepsis"}],"timeFrame":"From first dose of study intervention and up to 90 days after last dose or start of new anticancer therapy (maximum of 65.1 weeks of treatment)"}